Hansa Biopharma

Rwanda
Byumba, Northern Province, Rwanda, 220 07

Company profile

Hansa Biopharma company profile

Hansa Biopharma is a biopharmaceutical company that develops immunomodulatory treatments for people living with rare immunological diseases. They concentrate on creating novel, life-saving and life-changing treatments that can meet the critical, unmet medical needs of individuals with uncommon immunological disorders. To target pathogenic or disease-causing antibodies, they developed its proprietary antibody-cleaving enzyme technology platform. The company's diverse therapeutic pipeline has the potential to address significant unmet medical needs in transplantation, autoimmune diseases, gene therapy, and oncology indications.

Business identity

Contact email
[email protected]
Phone number
+46 46 16 56 70
Operating status
Active
Company type
For Profit
Employee range
101-250 employees
Revenue range
$1M-$10M
Founded
2007-01-01

Headquarters

Postal code
220 07
Country code
RW
Continent
Africa

Capital profile

Funding and company signals

Funding stage
IPO
Funding rounds
3
Total equity funding
$105.2M
Last funding
Post IPO Equity / $71M / 2025-10-02
Last equity funding
Post IPO Equity / $71M
Investors
8
Lead investors
3
Founders
1
Articles
162
Exited on
2019-02-01

Founders and investors

Founders

Join Hansa

Lead investors

Novaquest Capital ManagementPolar CapitalRedmile Group

Investors

BraidwellNovaquest Capital ManagementPolar CapitalRedmile GroupWoodline Partners